Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …

Abstract Background and Aims Management of Crohn's disease and ulcerative colitis has
typically relied upon treatment intensification driven by symptoms alone. However, a 'treat-to …

Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …

The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase
worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease …

Background & Aims Monitoring serum concentrations of tumor necrosis factor antagonists in
patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also …

Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the
inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis. Twenty …

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) of unknown etiology, probably
caused by a combination of genetic and environmental factors. The treatment of patients …

Abstract Background and Aims Reactive testing has emerged as the new standard of care
for managing loss of response to infliximab in inflammatory bowel disease [IBD]. Recent …

Background Biological tumor necrosis factor (TNF) inhibitors have revolutionized the
treatment of inflammatory bowel disease and redefined treatment goals to include mucosal …

Anti-tumour necrosis factor (TNF) therapies, such as infliximab, adalimumab, certolizumab
pegol and golimumab, have been proven to be effective for the treatment of patients with …